Results 291 to 300 of about 172,498 (401)

A genetic marker in the variable region of rabbit immunoglobulin heavy chain

, 1975
L R Mole
openalex   +2 more sources

Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design. [PDF]

Antib Ther
Wang M, Xu Q, Kong Y, Zhong Y, Yin F, Liu L, Yang Z, Ying T, Wu Y.   +8 more
europepmc   +1 more source

In vivofunctional analysis ofin vitroprotein binding sites in the immunoglobulin heavy chain enhancer

, 1988
Betty P. Tsao, Xiao‐Fan Wang, Craig L. Peterson, Kathryn Calame   +3 more
openalex   +2 more sources

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

Deep generative modeling captures maturation-dependent pairing patterns in human antibodies. [PDF]

iScience
Brönnimann L, Lemmin T, Rodella C.
europepmc   +1 more source

Physical map of the 3′ region of the human immunoglobulin heavy chain locus: clustering of autoantibody-related variable segments in one haplotype.

, 1991
E K Shin, Fumihiko Matsuda, Hitoshi Nagaoka, Yosho Fukita, Takashi Imai, Kazuyo Yokoyama, E Soeda, Tasuku Honjo   +7 more
openalex   +2 more sources

Transcriptional and functional effects of mavacamten in multiple porcine and human models with hypertrophic cardiomyopathy

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Mavacamten (MAVA) is a novel small molecule inhibitor of cardiac myosin, mitigating cardiomyocyte hypercontractility in patients with hypertrophic obstructive cardiomyopathy (HOCM). Despite its recent approval for clinical use, the transcriptional and functional impacts of MAVA remain not well understood.
Elisa Kiselev, Wilson Agyapong, Bjarne Jürgens, Elisa Mohr, Shambhabi Chatterjee, Hannah J. Hunkler, Jawad Salman, Giuseppe Cipriano, Marco Bentele, Junqing Liu, Jonas Specht, Kaja S. Menge, Florian J. G. Waleczek, Jonas A. Haas, Anselm A. Derda, Kristina Sonnenschein, Anika Gietz, Susanne Neumüller, Angelika Pfanne, Oliver Beetz, Michael Pflaum, Bettina Wiegmann, Yiangos Psaras, Christopher Toepfer, Robert Zweigerdt, Ante Radocaj, Theresia Kraft, Andre Zeug, Evgeni Ponimaskin, Wilhelm Korte, Alexander Horke, Arjang Ruhparwar, Maximilian Fuchs, Ke Xiao, Christian Bär, Natalie Weber, Thomas Thum   +36 more
wiley   +1 more source

Complement proteins associated with circulatory and glomerular IgA-containing immune complexes in patients with IgA nephropathy. [PDF]

Sci Rep
Tsuji Y, Ohyama Y, Saitoh S, Enomoto T, Hirayama M, Yamaguchi H, Nishioka T, Mizuno T, Tsuboi N, Novak J, Takahashi K.   +10 more
europepmc   +1 more source

EMB‐01, a Tetravalent Bispecific Antibody, Inducing Co‐Degradation of EGFR and c‐Met for Enhanced Anti‐Tumor Efficacy

Cancer Science, EarlyView.
As the breakthrough bispecific antibody targeting EGFR and c‐Met, EMB‐01 drives potent anti‐tumor efficacy by co‐degradation of both receptors. ABSTRACT The bispecific antibody EMB‐01 (bafisontamab), constructed using EpimAb's proprietary FIT‐Ig platform, is designed to simultaneously target epidermal growth factor receptor (EGFR) and receptor tyrosine
Jing Gao, Xi Jiao, Fang Ren, Xuan Wu, Jingyun Tan, Yuezong Bai, Yan Dai, Lixia Shen, Chengbin Wu, Lin Shen   +9 more
wiley   +1 more source

The making of multispecific immunoglobulins - a clinical perspective. [PDF]

MAbs
Brinkmann U, Kontermann RE.
europepmc   +1 more source